Skip to Content
Merck
  • Therapeutic efficacy of Ac-DMQD-CHO, a caspase 3 inhibitor, for rat spinal cord injury.

Therapeutic efficacy of Ac-DMQD-CHO, a caspase 3 inhibitor, for rat spinal cord injury.

Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia (2008-04-02)
Osman Akdemir, Ismail Berksoy, Alper Karaoğlan, Seref Barut, Kaya Bilguvar, Beyazit Cirakoğlu, Elife Sahan, Ahmet Colak
ABSTRACT

We investigated the therapeutic efficacy of Ac-DMQD-CHO, a caspase-3 inhibitor, and functional recovery in spinal cord injury in a rat model. Thirty rats were randomized into three groups of 10 each. In groups 2 and 3, spinal cord trauma was produced in the thoracic region. Group 3 rats were treated with Ac-DMQD-CHO. Treatment responses were evaluated based on histopathological and TUNEL staining findings at 24 h and 5 days post-injury. Neurologic performance was assessed during and following treatment. Twenty-four hours after injury, light microscopy examination revealed diffuse hemorrhagic necrosis, edema, vascular thrombi, and polymorphonuclear leukocyte infiltration in group 2 and 3 rats, but cavitation and demyelinization were less prominent in group 3. At this time point, treatment of the rats with Ac-DMQD-CHO significantly reduced the number of apoptotic cells. Traumatic injury to the spinal cord causes apoptosis and administration of Ac-DMQD-CHO decreases apoptosis and improves functional outcome.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Caspase 3 Substrate
Sigma-Aldrich
Caspase 3 Substrate (PKC), fluorogenic
Sigma-Aldrich
Caspase 3 Substrate (PKC), chromogenic
Sigma-Aldrich
Caspase 3 Apopain Substrate